Great Lakes Advisors LLC has decreased its stake in Ironwood Pharmaceuticals, Inc. (IRWD:NSD) by 3.1% during Q3, as per the latest filing with the Securities and Exchange Commission.
The institutional investor now holds 713,805 shares of the IRWD stock, after selling 22,843 shares during the period. Great Lakes Advisors LLC’s current holdings in Ironwood Pharmaceuticals are valued at $7.39 million.
Hedge Funds Holdings:
Other hedge funds have also made changes to their positions in Ironwood Pharmaceuticals recently. Gladius Capital Management LP bought a new stake in Q2, valued at $55,000. Banque Cantonale Vaudoise acquired a new position in Q2 worth $58,000, while Captrust Financial Advisors increased its holdings by 441.7% in Q2, owning 6,690 shares worth $77,000. Lazard Asset Management LLC bought a new position in Q1 valued at $78,000, and Quantbot Technologies LP acquired a new stake worth $109,000.
IRWD Stock-Insider Transactions:
In related news, CEO Thomas A. McCourt sold 110,962 shares of IRWD stock in a transaction on January 5th, at an average price of $12.07. Following the sale, the CEO now owns 712,440 shares of the IRWD stock, valued at $8.59 million. Currently, 13.10% of the stock is owned by corporate insiders.
IRWD Stock Price Perfromance:
Ironwood Pharmaceuticals Inc. (IRWD:NSD) opened at $11.27 on Thursday, with a 52-week low of $9.73 and a 52-week high of $12.95.
The company has a 50-day moving average price of $11.83 and a 200-day moving average price of $11.35. Ironwood Pharmaceuticals has a market cap of $1.73 billion, a debt-to-equity ratio of 0.67, and a beta of 0.94. The firm’s P/E ratio is 11.86.
Company Profile:
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.
It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.
The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
